Ovarian Cancer
Evidence-based overview of mebendazole in ovarian cancer, including metastasis, tubulin, and Akt / NF-κB findings
Mebendazole has strong mechanistic interest in ovarian cancer, especially because it appears to affect metastasis, apoptosis, and key survival pathways.
Overview
The ovarian-cancer literature focuses on tubulin disruption, apoptosis, invasion, and suppression of Akt, NF-κB, and β-catenin-related signalling.
Key findings
Mebendazole inhibits tubulin polymerisation and disrupts cell division
Promotes apoptosis in ovarian cancer cell lines
Suppresses Akt, NF-κB, and β-catenin pathways
Reduces metastatic and invasive behaviour in preclinical models
Clinical positioning
This remains a preclinical area, but one with strong pathway relevance and real interest for future repurposing work.
References
Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines
https://pmc.ncbi.nlm.nih.gov/articles/PMC11763501/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.